View article

The immune system has proven to be involved in ovarian cancer (OC) disease, yet, clinical immunotherapeutic trials have not resulted in convincing successes. Innate immunosuppression is currently left untackled. Anti-TIM3 (T-cell immunoglobulin and mucin-domain containing-3) has a potential advantage for OC immunotherapy, since it can manipulate the function of innate (macrophages and dendritic cells) and adaptive (CD4+, CD8+ and regulatory T-cells) immune cells.

Female C57BL/6 mice were inoculated intraperitoneally (IP) with 5x10^6 ID8-fLuc OC cells. Treatment was initiated 20 days post inoculation and consisted of carboplatinum-paclitaxel (C/P) chemotherapy (100mg/kg and 10mg/kg respectively) through a single IP injection with or without biweekly IP administration of anti-TIM3 (InVivoMAb anti-mouse TIM3 (CD366)) (350µg/injection) for three or four weeks in …